Zacks: Analysts Anticipate Teladoc Inc (TDOC) Will Announce Quarterly Sales of $107.79 Million

Equities research analysts predict that Teladoc Inc (NYSE:TDOC) will post sales of $107.79 million for the current quarter, Zacks Investment Research reports. Eleven analysts have made estimates for Teladoc’s earnings, with the highest sales estimate coming in at $111.20 million and the lowest estimate coming in at $107.00 million. Teladoc posted sales of $68.65 million during the same quarter last year, which would indicate a positive year over year growth rate of 57%. The firm is expected to report its next quarterly earnings report on Wednesday, November 7th.

On average, analysts expect that Teladoc will report full year sales of $407.92 million for the current fiscal year, with estimates ranging from $406.57 million to $409.80 million. For the next year, analysts forecast that the firm will post sales of $541.54 million per share, with estimates ranging from $531.04 million to $556.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Teladoc.

Teladoc (NYSE:TDOC) last released its quarterly earnings data on Wednesday, August 1st. The health services provider reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.01. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The firm had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $91.56 million. During the same period in the previous year, the business posted ($0.28) earnings per share. The company’s revenue for the quarter was up 112.1% compared to the same quarter last year.

A number of equities analysts have commented on TDOC shares. KeyCorp lifted their price objective on shares of Teladoc from $74.00 to $90.00 and gave the stock an “overweight” rating in a research report on Monday, August 27th. Berenberg Bank assumed coverage on shares of Teladoc in a research report on Monday, July 9th. They set a “buy” rating and a $72.00 price objective for the company. Jefferies Financial Group set a $74.00 target price on Teladoc and gave the stock a “buy” rating in a report on Wednesday, July 11th. Leerink Swann assumed coverage on Teladoc in a report on Thursday, August 16th. They set an “outperform” rating and a $90.00 target price for the company. Finally, Wells Fargo & Co reissued a “buy” rating and set a $70.00 target price on shares of Teladoc in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Teladoc currently has an average rating of “Buy” and an average target price of $65.10.

TDOC stock opened at $77.75 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.14 and a quick ratio of 3.14. Teladoc has a one year low of $27.30 and a one year high of $79.64. The firm has a market cap of $5.43 billion, a price-to-earnings ratio of -47.12 and a beta of 0.58.

In related news, President Peter A. Mcclennen sold 91,072 shares of the business’s stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $65.84, for a total value of $5,996,180.48. Following the completion of the transaction, the president now owns 61,660 shares of the company’s stock, valued at $4,059,694.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Adam C. Vandervoort sold 5,550 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $77.67, for a total value of $431,068.50. Following the completion of the transaction, the insider now directly owns 2,934 shares of the company’s stock, valued at approximately $227,883.78. The disclosure for this sale can be found here. Insiders have sold 242,497 shares of company stock valued at $16,108,269 in the last three months. Insiders own 3.95% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. CWM LLC raised its stake in Teladoc by 2.1% in the second quarter. CWM LLC now owns 53,632 shares of the health services provider’s stock valued at $3,113,000 after purchasing an additional 1,078 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Teladoc by 68.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock valued at $116,000 after purchasing an additional 1,171 shares in the last quarter. Swiss National Bank raised its stake in Teladoc by 1.7% in the first quarter. Swiss National Bank now owns 94,400 shares of the health services provider’s stock valued at $3,804,000 after purchasing an additional 1,600 shares in the last quarter. Amalgamated Bank raised its stake in Teladoc by 22.3% in the second quarter. Amalgamated Bank now owns 9,472 shares of the health services provider’s stock valued at $550,000 after purchasing an additional 1,724 shares in the last quarter. Finally, LPL Financial LLC raised its stake in Teladoc by 18.6% in the first quarter. LPL Financial LLC now owns 11,431 shares of the health services provider’s stock valued at $461,000 after purchasing an additional 1,791 shares in the last quarter.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Moving Average (MA)

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply